These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

523 related items for PubMed ID: 21970659

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE).
    Galetta D, Pisconti S, Cinieri S, Pappagallo GL, Gebbia V, Borsellino N, Maiello E, Rinaldi A, Montrone M, Rizzo P, Marzano N, Sasso N, Febbraro A, Colucci G.
    Clin Lung Cancer; 2011 Nov; 12(6):402-6. PubMed ID: 21831718
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
    Patel JD, Bonomi P, Socinski MA, Govindan R, Hong S, Obasaju C, Pennella EJ, Girvan AC, Guba SC.
    Clin Lung Cancer; 2009 Jul; 10(4):252-6. PubMed ID: 19632943
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH, Gröschel A, Sebastian M, Andreas S, Müller T, Schneller F, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M.
    Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
    [Abstract] [Full Text] [Related]

  • 8. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
    Ciuleanu T, Tsai CM, Tsao CJ, Milanowski J, Amoroso D, Heo DS, Groen HJ, Szczesna A, Chung CY, Chao TY, Middleton G, Zeaiter A, Klingelschmitt G, Klughammer B, Thatcher N.
    Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877
    [Abstract] [Full Text] [Related]

  • 9. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
    Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Y, Oyee J, Dickson R, Davis H, Green J, McKenna E, Pearson M.
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan.
    Ahn MJ, Tsai CM, Hsia TC, Wright E, Chang JW, Kim HT, Kim JH, Kang JH, Kim SW, Bae EJ, Kang M, Lister J, Walzer S.
    Asia Pac J Clin Oncol; 2011 Jun; 7 Suppl 2():22-33. PubMed ID: 21585705
    [Abstract] [Full Text] [Related]

  • 13. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
    Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smit EF, Ardizzoni A.
    Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy.
    Walzer S, Chouaid C, Lister J, Gultyaev D, Vergnenegre A, de Marinis F, Meng J, de Castro Carpeno J, Crott R, Kleman M, Ngoh C.
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):121-8. PubMed ID: 25248391
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
    Mir O, Boudou-Rouquette P, Giroux J, Chapron J, Alexandre J, Gibault L, Ropert S, Coriat R, Durand JP, Burgel PR, Dusser D, Goldwasser F.
    Lung Cancer; 2012 Jul; 77(1):104-9. PubMed ID: 22364783
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
    Zeng X, Peng L, Li J, Chen G, Tan C, Wang S, Wan X, Ouyang L, Zhao Z.
    Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.